These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36997361)

  • 1. Single-drug immunosuppression is associated with noninferior medium-term survival in pediatric heart transplant recipients.
    Watelle L; Touré M; Lamour JM; Kemna MS; Spinner JA; Hoffman TM; Carlo WF; Ballweg JA; Greenway SC; Dallaire F
    J Heart Lung Transplant; 2023 Aug; 42(8):1074-1081. PubMed ID: 36997361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction.
    Carlo WF; Padilla LA; Xu W; Carboni MP; Kleinmahon JA; Sparks JP; Rudraraju R; Villa CR; Singh TP
    J Heart Lung Transplant; 2022 Dec; 41(12):1773-1780. PubMed ID: 36241468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients.
    Singh TP; Faber C; Blume ED; Worley S; Almond CS; Smoot LB; Dillis S; Nasman C; Boyle GJ
    J Heart Lung Transplant; 2010 May; 29(5):517-22. PubMed ID: 20061164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience.
    Chen TT; Greene MM; Everitt MD; Simpson KE
    Pediatr Transplant; 2023 Mar; 27(2):e14438. PubMed ID: 36397270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
    Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J
    J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006.
    Na R; Laaksonen MA; Grulich AE; Webster AC; Meagher NS; McCaughan GW; Keogh AM; Vajdic CM
    Clin Transplant; 2015 Nov; 29(11):978-90. PubMed ID: 26278925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance steroid use at 30 days post-transplant and outcomes of pediatric heart transplantation: A propensity matched analysis of the Pediatric Heart Transplant Study database.
    Auerbach SR; Kukreja M; Gilbert D; Bastardi H; Feingold B; Knecht K; Kaufman BD; Brown RN; Miyamoto SD
    J Heart Lung Transplant; 2015 Aug; 34(8):1066-72. PubMed ID: 25980572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to tacrolimus alone compared to full immunosuppression following cardiac transplantation (TACTFUL).
    Pearston AP; Ingemi AI; Shaeffer ZA; Cameron CM; Biagi KT; Gobble M; Yehya A; Baran DA
    Clin Transplant; 2023 Dec; 37(12):e15140. PubMed ID: 37733704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results.
    Baran DA; Segura L; Kushwaha S; Courtney M; Correa R; Fallon JT; Cheng J; Lansman SL; Gass AL
    J Heart Lung Transplant; 2001 Jan; 20(1):59-70. PubMed ID: 11166613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.
    Greenway SC; Butts R; Naftel DC; Pruitt E; Kirklin JK; Larsen I; Urschel S; Knecht K; Law Y
    J Heart Lung Transplant; 2016 Apr; 35(4):457-65. PubMed ID: 26746989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant mortality and graft failure after induction immunosuppression among Black heart transplant recipients in the United States.
    Salia S; Mostofsky E; Gupta S; Lehman L; Barrera FJ; Liou L; Motiwala SR; Mittleman MA
    Am J Transplant; 2022 Nov; 22(11):2586-2597. PubMed ID: 35758522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the United Network for Organ Sharing policy change on induction immunosuppression practice patterns and outcomes in adult heart transplant recipients.
    Jennings DL; Baker WL
    Pharmacotherapy; 2023 Feb; 43(2):115-121. PubMed ID: 36588475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of children receiving ABO-incompatible versus ABO-compatible heart transplantation: a multicentre cohort study.
    Urschel S; Ballweg JA; Cantor RS; Koehl DA; Reinhardt Z; Zuckerman WA; Dipchand AI; Kanter KR; Sparks J; McCoy M; Kirklin JK; Carlo WF
    Lancet Child Adolesc Health; 2021 May; 5(5):341-349. PubMed ID: 33743201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
    Zang S; Zhang X; Niu J; Das BB
    Clin Transplant; 2023 Jan; 37(1):e14836. PubMed ID: 36259556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft survival of pediatric kidney transplant recipients selected for de novo steroid avoidance-a propensity score-matched study.
    Nehus EJ; Liu C; Lu B; Macaluso M; Kim MO
    Nephrol Dial Transplant; 2017 Aug; 32(8):1424-1431. PubMed ID: 28810723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of triple-drug-based immunosuppression in nonneonatal pediatric heart transplant recipients.
    Gajarski RJ; Smith EO; Denfield SW; Rosenblatt HM; Kearney D; Frazier OH; Radovancevic B; Price JK; Kertesz NJ; Towbin JA
    Transplantation; 1998 Jun; 65(11):1470-6. PubMed ID: 9645805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.